Capsugel will acquire Bend Research for an undisclosed amount, the companies have announced. Bend will become part of Capsugel’s Dosage Form Solutions (DFS) business unit.
Although the press release highlights Capsugel’s new “access to a premier suite of technologies to address customers’ most pressing formulation challenges for oral drug delivery,” both companies provide services for OINDP manufacturers, and Capsugel manufactures inhaler capsules and micro-dosing machines. Bend says that its “pulmonary drug delivery and nasal drug delivery technologies leverage more than 15 years’ experience in formulation development and particle engineering.”
Capsugel President & CEO Guido Driesen commented, “The Bend Research transaction highlights Capsugel’s commitment to investment and strategic growth since becoming a KKR portfolio company in the 2011 carve-out acquisition from Pfizer. Capsugel and Bend Research share common foundations in science and engineering, with values centered on innovation, quality and customer service. We have been impressed by Bend Research’s people, achievements and technology for some time and are delighted to combine our two companies. Capsugel’s vision of being a leading provider of innovative dosage forms and solutions to its healthcare customers is significantly advanced by this transaction.”
Bend CEO Rod Ray added, “We are ready to take Bend Research to the next level and the combination of our two companies is the best vehicle for helping us get there. We will expand our industry-leading capability to meet low bioavailability formulation challenges; strengthen the global footprint to support customer partnerships around the world; and enhance our ability to scale-up and commercially manufacture the customer compounds we help formulate. We are excited to be a part of Capsugel’s future.”
Read the Capsugel and Bend Research press release.
